{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:56:49Z","timestamp":1790870209957,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-026-01234-9","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:04:15Z","timestamp":1790179455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic and bioequivalence evaluation of teneligliptin hydrobromide tablets following single-dose administration in healthy Chinese volunteers under fasting and fed conditions"],"prefix":"10.1186","volume":"27","author":[{"given":"Zhaofeng","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefeng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"1234_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jare.2023.10.008","volume":"62","author":"F Niu","year":"2023","unstructured":"Niu F, Liu W, Ren Y, Tian Y, Shi W, Li M, et al. \u03b2-cell neogenesis: A rising star to rescue diabetes mellitus. J Adv Res. 2023;62:71\u201389. https:\/\/doi.org\/10.1016\/j.jare.2023.10.008.","journal-title":"J Adv Res"},{"issue":"7","key":"1234_CR2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41574-025-01114-y","volume":"21","author":"D Accili","year":"2025","unstructured":"Accili D, Deng Z, Liu Q. Insulin resistance in type 2 diabetes mellitus. Nat Rev Endocrinol. 2025;21(7):413\u201326. https:\/\/doi.org\/10.1038\/s41574-025-01114-y.","journal-title":"Nat Rev Endocrinol"},{"key":"1234_CR3","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2021","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021;183:109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"1234_CR4","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1016\/j.cmet.2021.09.012","volume":"33","author":"W Wei","year":"2021","unstructured":"Wei W, Jiang W, Han T, Tian M, Ding G, Li Y, et al. The future of prevention and treatment of diabetes with nutrition in China. Cell Metab. 2021;33(10):1908-9. https:\/\/doi.org\/10.1016\/j.cmet.2021.09.012.","journal-title":"Cell Metab"},{"issue":"12","key":"1234_CR5","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1016\/S2468-2667","volume":"9","author":"Y Xu","year":"2024","unstructured":"Xu Y, Lu J, Li M, Wang T, Wang K, Cao Q, et al. Diabetes in China part 1: epidemiology and risk factors. Lancet Public Health. 2024;9(12):e1089\u201397. https:\/\/doi.org\/10.1016\/S2468-2667. (24)00250-0.","journal-title":"Lancet Public Health"},{"issue":"9","key":"1234_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525\u201339. https:\/\/doi.org\/10.1038\/s41574-022-00690-7.","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"1234_CR7","doi-asserted-by":"publisher","first-page":"e1098","DOI":"10.1016\/S2468-2667","volume":"9","author":"Y Xu","year":"2024","unstructured":"Xu Y, Lu J, Li M, Wang T, Wang K, Cao Q, et al. Diabetes in China part 2: prevention, challenges, and progress. Lancet Public Health. 2024;9(12):e1098\u2013104. https:\/\/doi.org\/10.1016\/S2468-2667. (24)00251-2.","journal-title":"Lancet Public Health"},{"issue":"1","key":"1234_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther. 2023;8(1):152. https:\/\/doi.org\/10.1038\/s41392-023-01400-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"1\u20133","key":"1234_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejphar.2012.09.024","volume":"696","author":"S Fukuda-Tsuru","year":"2012","unstructured":"Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012;696(1\u20133):194\u2013202. https:\/\/doi.org\/10.1016\/j.ejphar.2012.09.024.","journal-title":"Eur J Pharmacol"},{"key":"1234_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/DMSO.S106133","volume":"9","author":"SK Sharma","year":"2016","unstructured":"Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Teneligliptin in management of type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2016;9:251\u201360. https:\/\/doi.org\/10.2147\/DMSO.S106133.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1234_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.freeradbiomed.2020.07.030","volume":"160","author":"S Elumalai","year":"2020","unstructured":"Elumalai S, Karunakaran U, Moon JS, Won KC. High glucose-induced PRDX3 acetylation contributes to glucotoxicity in pancreatic \u03b2-cells: Prevention by Teneligliptin. Free Radic Biol Med. 2020;160:618\u201329. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2020.07.030.","journal-title":"Free Radic Biol Med"},{"key":"1234_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fphar.2018.00449","volume":"9","author":"X Li","year":"2018","unstructured":"Li X, Huang X, Bai C, Qin D, Cao S, Mei Q, et al. Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2018;9:449. https:\/\/doi.org\/10.3389\/fphar.2018.00449.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1234_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40265-019-01086-0","volume":"79","author":"A Ceriello","year":"2019","unstructured":"Ceriello A, De Nigris V, Iijima H, Matsui T, Gouda M. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs. 2019;79(7):733\u201350. https:\/\/doi.org\/10.1007\/s40265-019-01086-0.","journal-title":"Drugs"},{"issue":"11","key":"1234_CR14","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40261-015-0348-9","volume":"35","author":"LJ Scott","year":"2015","unstructured":"Scott LJ. Teneligliptin: a review in type 2 diabetes. Clin Drug Investig. 2015;35(11):765\u201372. https:\/\/doi.org\/10.1007\/s40261-015-0348-9.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"1234_CR15","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1463-1326.2012.01662.x","volume":"14","author":"T Eto","year":"2012","unstructured":"Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2012;14(11):1040\u20136. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01662.x.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1234_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF01061471","volume":"20","author":"D Hauschke","year":"1992","unstructured":"Hauschke D, Steinijans VW, Diletti E, Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm. 1992;20(5):557\u201361. https:\/\/doi.org\/10.1007\/BF01061471.","journal-title":"J Pharmacokinet Biopharm"},{"key":"1234_CR17","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.2147\/DDDT.S393675","volume":"16","author":"IS Goak","year":"2022","unstructured":"Goak IS, Lee JA, Jeong MH, Moon SJ, Kim MG. Pharmacokinetics of a Fixed-Dose Combination of Teneligliptin Hydrochloride Hydrate and Modified-Release Metformin Under Fasting and Fed Conditions in Healthy Subjects. Drug Des Devel Ther. 2022;16:4439\u201348. https:\/\/doi.org\/10.2147\/DDDT.S393675.","journal-title":"Drug Des Devel Ther"},{"key":"1234_CR18","unstructured":"Food and Drug Administration. Guidance for Industry: bioavailability and bioequivalence studies submitted in NDAs or INDs \u2014 general considerations. Food and Drug Administration Guidance Documents; 2003."},{"key":"1234_CR19","unstructured":"Food and Drug Administration. Guidance for Industry: food-effect bioavailability and fed bioequivalence studies. Food and Drug Administration Guidance Documents; 2002."},{"issue":"7","key":"1234_CR20","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/bcp.15629","volume":"90","author":"PJ Glerum","year":"2023","unstructured":"Glerum PJ, Yamada WM, Neely MN, Burger DM, Maliepaard M, Neef C. Interchangeability of generic drugs for subpopulations: Bioequivalence simulation from a nonparametric PK model of gabapentin generic drugs. Br J Clin Pharmacol. 2023;90(7):1576\u201385. https:\/\/doi.org\/10.1111\/bcp.15629.","journal-title":"Br J Clin Pharmacol"},{"key":"1234_CR21","doi-asserted-by":"publisher","first-page":"122758","DOI":"10.1016\/j.ijpharm.2023.122758","volume":"635","author":"Z Vinarov","year":"2023","unstructured":"Vinarov Z, Butler J, Kesisoglou F, Koziolek M, Augustijns P. Assessment of food effects during clinical development. Int J Pharm. 2023;635:122758. https:\/\/doi.org\/10.1016\/j.ijpharm.2023.122758.","journal-title":"Int J Pharm"},{"issue":"5","key":"1234_CR22","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s40618-023-02003-9","volume":"46","author":"R Pelluri","year":"2023","unstructured":"Pelluri R, Kongara S, Nagasubramanian VR, Mahadevan S, Chimakurthy J. Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes. J Endocrinol Invest. 2023;46(5):855\u201367. https:\/\/doi.org\/10.1007\/s40618-023-02003-9.","journal-title":"J Endocrinol Invest"},{"key":"1234_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00672-5","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan A-W, Collins GS, Hr\u00f3bjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. Lancet. 2025. https:\/\/doi.org\/10.1016\/S0140-6736(25)00672-5.","journal-title":"Lancet"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-026-01234-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01234-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-026-01234-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:15:23Z","timestamp":1790867723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40360-026-01234-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1186\/s40360-026-01234-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Clinical procedures were undertaken from April through September 2025 at The Affiliated Panyu Central Hospital of Guangzhou Medical University in accordance with the Declaration of Helsinki. The institution\u2019s Drug Clinical Trial Ethics Committee approved, before initiation, the protocol and its amendments, the informed consent form (ICF), and every later update to the trial documents (PYZXYYEC [2025-013 (YW)]-01). Public registration was entered first on chinadrugtrials.org.cn (Drug Clinical Trial Registration and Information Publicity Platform; CTR20252533) and subsequently, on a retrospective basis, on chictr.org.cn (Chinese Clinical Trial Registry; ChiCTR2500112749). Screening began only after each volunteer had signed written informed consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript submitted for publication. The content presented herein has not been published previously in any form and is not under consideration for publication elsewhere.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Trial conduct and manuscript preparation adhered to CONSORT 2025 and its applicable bioequivalence extensions [\n                      \n                      ]. The supplementary material includes the completed CONSORT 2025 checklist.","order":3,"name":"Ethics","label":"CONSORT statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"138"}}